Savara Inc Uncategorized Contracts & Agreements
67 Contracts & Agreements
- Description of Registered Securities (Filed With SEC on March 12, 2020)
- Amendment dated May 27, 2019 to the Business Transfer Agreement Between Savara Inc. and Serendex Pharmaceuticals A/S, dated May 13, 2016, between Savara Inc. and Serendex... (Filed With SEC on August 8, 2019)
- Research Program Award Letter Agreement between Savara Inc. and Cystic Fibrosis Foundation Therapeutics, Inc. dated September 30, 2013, as amended by Amendment No. 1, effective... (Filed With SEC on November 30, 2017)
- SUB-SUBLEASE AGREEMENT (Filed With SEC on March 28, 2017)
- SAVARA INC. March 19, 2012 (Filed With SEC on February 10, 2017)
- [THE REMAINDER OFTHIS PAGE IS INTENTIONALLY LEFT BLANK; THE SIGNATURE PAGE IMMEDIATELY FOLLOWS] (Filed With SEC on February 10, 2017)
- Mast Therapeutics, Inc. Amendment No. 1 to Lock-Up Agreement January 21, 2017 (Filed With SEC on January 23, 2017)
- Mast Therapeutics, Inc. Lock-Up Agreement January 6, 2017 (Filed With SEC on January 9, 2017)
- EXERCISABLE ON OR AFTER AUGUST , 2016 AND UNTIL 5:00 P.M. (NEW YORK TIME) ON THE EXPIRATION DATE (Filed With SEC on February 11, 2016)
- MAST THERAPEUTICS, INC. $30,000,000 SALESAGREEMENT (Filed With SEC on August 21, 2015)
- 12390 EL CAMINO REAL, SUITE 150 n SAN DIEGO, CA 92130 n TEL ###-###-#### n FAX ###-###-#### n MASTTHERAPEUTICS.COM n NYSE MKT: MSTX (Filed With SEC on October 31, 2014)
- FORM OF STOCKHOLDER AGREEMENT (Filed With SEC on May 5, 2014)
- MAST THERAPEUTICS, INC. $30,000,000 SALESAGREEMENT (Filed With SEC on February 10, 2014)
- EX-101 INSTANCE DOCUMENT (Filed With SEC on November 8, 2011)
- Financial Statements (Filed With SEC on May 9, 2011)
- Financial Statements (Filed With SEC on May 9, 2011)
- Financial Statements (Filed With SEC on May 9, 2011)
- Financial Statements (Filed With SEC on May 9, 2011)
- ADVENTRX Pharmaceuticals, Inc. ACCEPTED AND AGREED:/s/ Patrick Keran /s/ Brandi L. Roberts Patrick Keran President and Chief Operating Officer Brandi L. Roberts Date: 2/14/11 (Filed With SEC on March 22, 2011)
- Rodman & Renshaw, LLC o 1251 Avenue of the Americas, 20th Floor, New York, NY 10020 Tel: 212 ###-###-#### o Fax: 212 ###-###-#### o www.rodm.com o Member: FINRA, SIPC (Filed With SEC on January 7, 2011)
- Rodman & Renshaw, LLC o 1251 Avenue of the Americas, 20th Floor, New York, NY 10020 Tel: 212 ###-###-#### o Fax: 212 ###-###-#### o www.rodm.com o Member: FINRA, SIPC (Filed With SEC on May 3, 2010)
- reducing the incidence and severity of adverse effects; and (Filed With SEC on March 18, 2010)
- reducing the incidence and severity of adverse effects; and (Filed With SEC on March 18, 2010)
- reducing the incidence and severity of adverse effects; and (Filed With SEC on March 18, 2010)
- reducing the incidence and severity of adverse effects; and (Filed With SEC on March 18, 2010)
- Annex A (Filed With SEC on January 4, 2010)
- Rodman& Renshaw, LLC o 1251Avenue of the Americas, 20th Floor, New York, NY 10020 Tel: 212 ###-###-#### o Fax: 212 ###-###-#### o www.rodm.com o Member: FINRA, SIPC (Filed With SEC on October 5, 2009)
- Reducing the incidence and severity of adverse effects; and (Filed With SEC on September 25, 2009)
- THIRD AMENDMENT TO RIGHTS AGREEMENT (Filed With SEC on September 1, 2009)
- Annex A (Filed With SEC on August 5, 2009)
- Rodman& Renshaw, LLC 1251 Avenue of the Americas, 20thFloor, New York, NY 10020 Tel: 212 ###-###-#### Fax: 212 ###-###-#### www.rodm.com Member: FINRA, SIPC (Filed With SEC on June 30, 2009)
- Rodman & Renshaw, LLC 1251 Avenue of the Americas, 20thFloor, New York, NY 10020 Tel: 212 ###-###-#### Fax: 212 ###-###-#### www.rodm.com Member: FINRA, SIPC (Filed With SEC on June 8, 2009)
- Current assets (Filed With SEC on May 15, 2009)
- Current assets (Filed With SEC on May 15, 2009)
- Current assets (Filed With SEC on May 15, 2009)
- Current assets (Filed With SEC on May 15, 2009)
- Current assets (Filed With SEC on May 15, 2009)
- Reducing the incidence and severity of adverse effects; and (Filed With SEC on March 27, 2009)
- Reducing the incidence and severity of adverse effects; and (Filed With SEC on March 27, 2009)
- Current assets (Filed With SEC on August 11, 2008)